Page 65 - Read Online

Bibi et al. J Transl Genet Genom 2024;8:119-161 https://dx.doi.org/10.20517/jtgg.2023.50 Page 155

119. Wargowski E, Johnson LE, Eickhoff JC, et al. Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with
metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine. J Immunother Cancer 2018;6:21.
DOI PubMed PMC
120. Dannull J, Diener PA, Prikler L, et al. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate
cancer. Cancer Res 2000;60:5522-8. PubMed
121. Kiessling A, Schmitz M, Stevanovic S, et al. Prostate stem cell antigen: Identification of immunogenic peptides and assessment of
+
reactive CD8 T cells in prostate cancer patients. Int J Cancer 2002;102:390-7. DOI
122. Matsueda S, Kobayashi K, Nonaka Y, Noguchi M, Itoh K, Harada M. Identification of new prostate stem cell antigen-derived
+
peptides immunogenic in HLA-A2 patients with hormone-refractory prostate cancer. Cancer Immunol Immunother 2004;53:479-89.
DOI PubMed
123. Matsueda S, Yao A, Ishihara Y, et al. A prostate stem cell antigen-derived peptide immunogenic in HLA-A24- prostate cancer
patients. Prostate 2004;60:205-13. DOI
124. de la Luz Garcia-Hernandez M, Gray A, Hubby B, Klinger OJ, Kast WM. Prostate stem cell antigen vaccination induces a long-
term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res 2008;68:861-9. DOI PubMed
125. Krupa M, Canamero M, Gomez CE, Najera JL, Gil J, Esteban M. Immunization with recombinant DNA and modified vaccinia virus
Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression. Vaccine 2011;29:1504-13. DOI
PubMed
126. Ross S, Spencer SD, Holcomb I, et al. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an
immunoconjugate. Cancer Res 2002;62:2546-53. PubMed
127. Saffran DC, Raitano AB, Hubert RS, Witte ON, Reiter RE, Jakobovits A. Anti-PSCA mAbs inhibit tumor growth and metastasis
formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci USA 2001;98:2658-63.
DOI PubMed PMC
128. Gu Z, Yamashiro J, Kono E, Reiter RE. Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and
inhibits tumor growth in vivo via a Fc-independent mechanism. Cancer Res 2005;65:9495-500. DOI
129. Olafsen T, Gu Z, Sherman MA, et al. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA)
antibody. J Immunother 2007;30:396-405. DOI
130. Feldmann A, Stamova S, Bippes CC, et al. Retargeting of T cells to prostate stem cell antigen expressing tumor cells: comparison of
different antibody formats. Prostate 2011;71:998-1011. DOI
131. Morgenroth A, Cartellieri M, Schmitz M, et al. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using
genetically engineered T-cells. Prostate 2007;67:1121-31. DOI
132. Murad JP, Tilakawardane D, Park AK, et al. Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and
endogenous protective immunity. Mol Ther 2021;29:2335-49. DOI PubMed PMC
133. Dorff TB, Narayan V, Forman SJ, et al. Novel redirected T-cell immunotherapies for advanced prostate cancer. Clin Cancer Res
2022;28:576-84. DOI PubMed PMC
134. Hempelmann JA, Lockwood CM, Konnick EQ, et al. Microsatellite instability in prostate cancer by PCR or next-generation
sequencing. J Immunother Cancer 2018;6:29. DOI
135. Fraune C, Simon R, Höflmayer D, et al. High homogeneity of mismatch repair deficiency in advanced prostate cancer. Virchows Arch
2020;476:745-52. DOI
136. Abida W, Cheng ML, Armenia J, et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to
immune checkpoint blockade. JAMA Oncol 2019;5:471-8. DOI PubMed PMC
137. Xu J, Kalos M, Stolk JA, et al. Identification and characterization of prostein, a novel prostate-specific protein. Cancer Res
2001;61:1563-8. PubMed
138. Kalos M, Askaa J, Hylander BL, et al. Prostein expression is highly restricted to normal and malignant prostate tissues. Prostate
2004;60:246-56. DOI
139. Musiyenko A, Bitko V, Barik S. Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene,
regulates prostein translation and invasiveness of prostate cancer LNCaP cells. J Mol Med 2008;86:313-22. DOI PubMed PMC
140. Kiessling A, Stevanovic S, Füssel S, et al. Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate
cancer-associated protein prostein. Br J Cancer 2004;90:1034-40. DOI PubMed PMC
141. Schmidt U, Fuessel S, Koch R, et al. Quantitative multi-gene expression profiling of primary prostate cancer. Prostate 2006;66:1521-
34. DOI
142. Friedman RS, Spies AG, Kalos M. Identification of naturally processed CD8 T cell epitopes from prostein, a prostate tissue-specific
vaccine candidate. Eur J Immunol 2004;34:1091-101. DOI PubMed
143. Swaya TO, Opondo D, Atandi DO, Guyah B, Magak NWG. Immunohistochemical analysis of prostein in needle core biopsies of
acinar and intraductal prostatic adenocarcinoma in Western Kenya population. J Cancer Sci Clin Ther 2022;6:269-75. Available
from: https://repository.maseno.ac.ke/handle/123456789/5358 [Last accessed on 12 Apr 2024].
144. Wolfgang CD, Essand M, Vincent JJ, Lee B, Pastan I. TARP: a nuclear protein expressed in prostate and breast cancer cells derived
from an alternate reading frame of the T cell receptor gamma chain locus. Proc Natl Acad Sci USA 2000;97:9437-42. DOI PubMed
PMC
145. Cheng WS, Giandomenico V, Pastan I, Essand M. Characterization of the androgen-regulated prostate-specific T cell receptor
gamma-chain alternate reading frame protein (TARP) promoter. Endocrinology 2003;144:3433-40. DOI PubMed